Skip to content
Pharma Observatory a Scientist.com platform

Organization (Industry)

Beijing InnoCare Pharma Tech Co., Ltd. (China)

ClinicalTrials.gov lists Beijing InnoCare Pharma Tech Co., Ltd. (China) as lead sponsor of 57 trials. It has 71 active development programs and 11 approved assets.

CN Industry
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

10 0 2018 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 6 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 7 in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

This page covers Beijing InnoCare Pharma Tech Co., Ltd. (China): 57 lead-sponsored trials and 1 legal-entity registration.

Get the Beijing InnoCare Pharma Tech Co., Ltd. (China) report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (29)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Lymphoma 10
Lymphoma, Non-Hodgkin 10
Lymphoma, Mantle-Cell 5
Recurrence 5
Lymphoma, B-Cell 4

Trials by start year as sponsor or collaborator (9)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 6
2025 8
2024 8
2023 9
2022 9
2021 10
2020 5
2019 5
2018 4

Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 38 trials still running at the 2026-10-09 snapshot; 20 of 38 predicted trials reach the 36-month horizon; registered median of 18 months across 13 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (71)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Orelabrutinib Lymphoma Phase 3 5
Orelabrutinib Lymphoma, Non-Hodgkin Phase 3 5
Orelabrutinib Lymphoma, Mantle-Cell Phase 3 3
ICP-248 Lymphoma, Mantle-Cell Phase 3 2
ICP-248 Lymphoma, Non-Hodgkin Phase 3 2

Approved assets (11)

Shown in this order: max phase first.

Approved assets
Drug Trials
RITUXIMAB 5
LENALIDOMIDE 2
Chlorambucil 1
OXALIPLATIN 1
GEMCITABINE 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
64% hit target (n=14) 45% on time (n=11)

Journals published in (6)

Shown in this order: most published in first.

Journals published in
Journal Publications
Advances in hematology 1
American journal of hematology 1
Anti-cancer drugs 1
Blood advances 1
EClinicalMedicine 1

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
14 9 2025-08-19

Organization relationships (4)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Peking Union Medical College Hospital Co sponsors trial with 1
GCP ClinPlus Co., Ltd. Co sponsors trial with 1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences Co sponsors trial with 1
BioRay Pharmaceutical Co., Ltd. Co sponsors trial with 1

Latest dated events (78)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-08 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-07-03 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-04-27 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-03-13 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (142)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ALB Trial sponsor Named in trial inclusion criteria
AQP4 Trial collaborator Named in trial inclusion criteria
BTK Trial sponsor Named in trial inclusion criteria
CD79B Trial sponsor Named in trial inclusion criteria
F2 Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.